Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Heise

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of Virology|November 29, 2023
Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variantsKan Li, Richard H C Huntwork, Gillian Q Horn, et al.
Mbio|October 28, 2010
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signalingXinxia Peng, Lisa Gralinski, Christopher D Armour, et al.
Journal of Medicinal Chemistry|July 3, 2024
More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-<i>a</i>]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus ReplicationHan Wee Ong, Xuan Yang, Jeffery L Smith, et al.
Plos Pathogens|September 7, 2021
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infectionQibin Geng, Wanbo Tai, Victoria K Baxter, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Nature Medicine|July 3, 2024
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Nature Medicine|May 25, 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Infection Of Rhesus Macaques With O'nyong-nyong Virus UVIR-O804 Recapitulates Key Aspects of Human Clinical DiseaseHannah K Jaeger, Michael Denton, Takeshi F Andoh, et al.
Research Square|November 14, 2023
Adjuvant-dependent effects on the safety and efficacy of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirusMark Heise, Jacob Dillard, Sharon Taft-Benz, et al.
Genome Medicine|June 15, 2021
Landscape and selection of vaccine epitopes in SARS-CoV-2Christof C Smith, Kelly S Olsen, Kaylee M Gentry, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of Virology|November 29, 2023
Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variantsKan Li, Richard H C Huntwork, Gillian Q Horn, et al.
Mbio|October 28, 2010
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signalingXinxia Peng, Lisa Gralinski, Christopher D Armour, et al.
Journal of Medicinal Chemistry|July 3, 2024
More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-<i>a</i>]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus ReplicationHan Wee Ong, Xuan Yang, Jeffery L Smith, et al.
Plos Pathogens|September 7, 2021
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infectionQibin Geng, Wanbo Tai, Victoria K Baxter, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Nature Medicine|July 3, 2024
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Nature Medicine|May 25, 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Infection Of Rhesus Macaques With O'nyong-nyong Virus UVIR-O804 Recapitulates Key Aspects of Human Clinical DiseaseHannah K Jaeger, Michael Denton, Takeshi F Andoh, et al.
Research Square|November 14, 2023
Adjuvant-dependent effects on the safety and efficacy of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirusMark Heise, Jacob Dillard, Sharon Taft-Benz, et al.
Genome Medicine|June 15, 2021
Landscape and selection of vaccine epitopes in SARS-CoV-2Christof C Smith, Kelly S Olsen, Kaylee M Gentry, et al.
Pageof 6